Head to Head Comparison: DiaSorin (OTCMKTS:DSRLF) and IM Cannabis (NASDAQ:IMCC)

DiaSorin (OTCMKTS:DSRLF) and IM Cannabis (NASDAQ:IMCC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.

Earnings and Valuation

This table compares DiaSorin and IM Cannabis”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaSorin	$1.28 billion	N/A	$203.55 million	N/A	N/A
IM Cannabis	$39.44 million	0.21	-$7.72 million	($0.78)	-2.00

DiaSorin has higher revenue and earnings than IM Cannabis.

Institutional & Insider Ownership

7.7% of IM Cannabis shares are held by institutional investors. 5.9% of IM Cannabis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares DiaSorin and IM Cannabis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DiaSorin	N/A	N/A	N/A
IM Cannabis	-9.47%	-134.35%	-11.66%

Volatility and Risk

DiaSorin has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for DiaSorin and IM Cannabis, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaSorin	0	0	2	0	3.00
IM Cannabis	1	0	0	0	1.00

Summary

DiaSorin beats IM Cannabis on 7 of the 10 factors compared between the two stocks.

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

About IM Cannabis

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.